Millennium Management
JSPR icon

Millennium Management’s Jasper Therapeutics JSPR Stock Holding History

Millennium Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,800
Closed -$359K – 6149
2024
Q4 		$359K Buy
+16,800
New +$350K ﹤0.01% 4970

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management's JSPR Position: Q1 2026 in Review

Millennium Management increased its Jasper Therapeutics (JSPR) stake by 51% in Q1 2026, buying an estimated $755K and bringing the position to 1,617,531 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #4141.

Millennium Management first reported a position in JSPR in Q1 2021 and has held it in 15 quarters since. The position peaked at $3.27M in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Millennium Management held 1,617,531 shares of Jasper Therapeutics worth $1.42M as of Q1 2026.
  • Millennium Management bought 543,748 Jasper Therapeutics shares in Q1 2026, an estimated $755K.
  • Jasper Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4141 holding.
  • Millennium Management first reported a position in Jasper Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Millennium Management's Jasper Therapeutics position peaked at $3.27M in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.